Celiac plexus neurolysis in the management of unresectable pancreatic cancer: When and how?

Table 1 Early endoscopic ultrasound-celiac plexus neurolysis vs systemic analgesic therapy: Pain relief and narcotic consumption with or without chemo-XRT[12]

EUS-CPNvscontrol	After 1 mo (95%CI)	After 3 mo (95%CI)
Difference in mean % change in pain relief:
No chemo-XRT1	-59.6% (-95.4 to -27.6)1	-85.8% (-127.6 to -51.3)1
Chemo-XRT	31.0% (-34.3 to 106.2)	-45.6% (-72.6 to -23.3)1
Difference in mean change in MEQ consumption:
No chemo-XRT	-2.4 mg (-58.4 to 60.8)	-144.5 mg (-291 to -30)1
Chemo-XRT	11.4 mg (-23.7 to 39.4)	26.1 mg (-12.2 to 56.5)

¹Statistically significant P < 0.05. EUS-CPN: Endoscopic ultrasound-celiac plexus neurolysis; Chemo-XRT: Chemotherapy and radiation therapy; MEQ: Morphine equivalent.